Effect of an Anti-inflammatory Diet on Patients With Cervical Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

136 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-16

Study Completion Date

2024-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

During radiation therapy (RT) to pelvic tumors, the small intestine, colon and rectum are inevitably included in the radiation field and are healthy tissues that suffer damage as an adverse effect. Pelvic radiation disease (PRD) is the group of gastrointestinal symptoms experienced by patients that receive pelvic radiation. Intestinal inflammation, tissue damage, oxidative stress and tumor metabolism lead the patient to a catabolic state associated with an increase in energy demands. Also, the painful abdominal symptoms restrict the patients' food intake, leading the patients that develop PRD to an increased risk to develop protein-energy malnutrition and micronutrient deficiencies, all of which affect the patients' quality of life. Studies developed in patients with inflammatory bowel disease have suggested that probiotics may have an anti-inflammatory effect in the intestine. In addition, micronutrients and trace elements provide antioxidant capacity and exert immune-modulating effects during periods of intestinal inflammation. Thus, probiotics and immune-modulating nutrients may provide a means to diminish intestinal inflammation and symptoms associated with PRD. In this project the investigators propose that the nutritional management of cervical cancer patients be based on an anti-inflammatory diet, taking into account the nutritional status, age, comorbidities that the patient may present and symptoms developed during treatment. The nutritional intervention will include food rich in immune-modulating nutrients: omega-3 fatty acids, soluble fiber, antioxidants and polyphenols, and probiotics.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Preoperative High Protein vs Immunodiet in Surgical Cancer Patients

NCT03980704

General Surgery Cancer of Colon

COMPLETED PHASE4

Study to Prevent Radiation Induced Damage to Bowel Using a Prebiotic Enhanced Diet.

NCT01414517

Radiation Enteritis Radiation Proctitis

UNKNOWN PHASE3

"The Impact of Immunonutrition on Gut Microbiota-related Aspects in Colorectal Cancer and Gastric Cancer Patients"

NCT04980950

Gastric Cancer Colorectal Cancer

UNKNOWN NA

Energy Balance Interventions for Colorectal Cancer Prevention

NCT00653484

Colorectal Cancer Obesity

COMPLETED NA

Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial

NCT04534075

Malignant Neoplasm Malignant Neoplasm of Rectum Malignant Neoplasm of Anus +7 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cervical cancer is the second most frequent cancer in Mexican women, representing 16.9% of the total female population. At the National Cancer Institute of Mexico (Instituto Nacional de Cancerología), 80% cervical cancer patients arrive at locally advanced stages (IB2-IVA). Standard treatment for these stages is based on concomitant chemo-radiotherapy. During radiation therapy (RT) to pelvic tumors, the small intestine, colon and rectum are inevitably included in the radiation field and are healthy tissues that suffer damage as an adverse effect. Pelvic radiation disease (PRD) is the group of gastrointestinal symptoms experienced by patients that receive pelvic radiation. Acute PRD occurs during the time of treatment in 60 to 80% patients, symptoms include nausea, diarrhea, tenesmus, abdominal pain, urgency, mucositis, anorexia, bleeding and fatigue; these symptoms limit cancer treatment and affect the patients' quality of life. Chronic PRD is a progressive condition and a problem for cervical cancer survivors, symptoms include altered intestinal traffic, altered intestinal motility and nutrient malabsorption. The intestinal immune system plays an important role in the development of PRD and the secondary effects of RT. Intestinal inflammation, tissue damage, oxidative stress and tumor metabolism lead the patient to a catabolic state associated with an increase in energy demands. Also, the painful abdominal symptoms restrict the patients' food intake, leading the patients that develop PRD to an increased risk to develop protein-energy malnutrition and micronutrient deficiencies, all of which affect the patients' quality of life. Among some of the nutritional intervention assays for patients with PRD, some have described that a low residue diet, restricted in fat (20-25%), lactose (5g) and fiber (20g), reduces the frequency and severity of diarrhea; however, this dietary intervention does not prevent weight loss or malnutrition in patients. Furthermore, low residue diets limit the beneficial effect of dietary fiber and fatty acids that may aid in the inflammatory response. Likewise, patients with inflammatory bowel disease (IBD) develop similar symptoms to PRD. Studies developed in these patients have suggested that probiotics may have an anti-inflammatory effect in the intestine. In addition, micronutrients and trace elements provide antioxidant capacity and exert immune-modulating effects during periods of intestinal inflammation. Thus, probiotics and immune-modulating nutrients may provide a means to diminish intestinal inflammation and symptoms associated with PRD. In this project the investigators propose that the nutritional management of cervical cancer patients be based on an anti-inflammatory diet, taking into account the nutritional status, age, comorbidities that the patient may present and symptoms developed during treatment. The individualized energy requirements and nutrient proportions for patients without comorbidities, and for patients with comorbidities such as obesity, type 2 diabetes, hypertension and renal dysfunction, will be calculated according to the recommendations derived from the Consensus of Nutrition in patients with cancer treated with chemo-radiotherapy to the abdominopelvic area. Furthermore, the nutritional intervention will include food rich in immune-modulating nutrients: omega-3 fatty acids, soluble fiber, antioxidants and polyphenols, and probiotics. Because the low residue diet is routinely used for patients that receive pelvic radiation in other institutions, the anti-inflammatory nutritional intervention will be compared with the low residue diet.

An open controlled randomized clinical trial will be performed on women with locally advanced cervical cancer. Candidates will be randomly assigned to one of the two dietary interventions. Experimental group will receive an anti-inflammatory diet with an energy intake of 28-31 kcal/kg/day, based on 30-40% fat, 20% protein, and 40-50% carbohydrates, the diet will include foods rich in omega-3 fatty acids, soluble fiber, antioxidants and polyphenols, and probiotics. The control group will receive a low residue diet with 28-91 kcal/kg/day, based on 20% fat, 20% protein, and 60% carbohydrates, with no more than 20g fiber and 5g of lactose. In both groups, before, during and after cancer treatment, a thorough nutritional evaluation will be performed, gastrointestinal toxicity will be assessed, and serum cytokine levels and fecal calprotectin and lactoferrin levels will be determined to establish the local and systemic inflammatory response. The quality of life of patients will also be assessed before and after treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Cancer Uterine Cervical Neoplasm Pelvic Inflammatory Disease Radiation Toxicity Diet Modification

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anti-inflammatory Diet

Dietary intervention providing:

Energy: 28-31 kcal/kg/day. Protein: 20-30%. Fat: 30-40%. Carbohydrates: 40-50%. The diet will be individualized according to the patients' comorbidities (obesity, type 2 diabetes, hypertension, renal insufficiency).

This group will include the consumption of foods that contain immune modulating nutrients:

Omega-3 fatty acids, antioxidants, soluble fiber, probiotics. The recommendation to include these foods will be made according to the patients' access to food in their home area.

Group Type EXPERIMENTAL

Omega-3 fatty acids

Intervention Type OTHER

Diet will include foods rich in omega-3 fatty acids.

Antioxidants

Intervention Type OTHER

Diet will include foods rich in antioxidant vitamins, trace elements, and polyphenols.

Soluble fiber

Intervention Type OTHER

Diet will include foods rich in soluble fiber.

Probiotics

Intervention Type OTHER

Diet will include foods rich in probiotics.

Low residue Diet

Dietary intervention providing:

Energy: 28-31 kcal/kg/day. Protein: 20%. Fat: 20%. Carbohydrates: 60%. Diet will have lactose restriction, fiber restriction and fat restriction.

Group Type ACTIVE_COMPARATOR

Lactose restriction

Intervention Type OTHER

Diet will be restricted to 5g lactose/day

Fiber restriction

Intervention Type OTHER

Diet will be restricted to 20g fiber/day

Fat restriction

Intervention Type OTHER

Diet will be restricted to 20% total energy intake

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omega-3 fatty acids

Diet will include foods rich in omega-3 fatty acids.

Intervention Type OTHER

Antioxidants

Diet will include foods rich in antioxidant vitamins, trace elements, and polyphenols.

Intervention Type OTHER

Soluble fiber

Diet will include foods rich in soluble fiber.

Intervention Type OTHER

Probiotics

Diet will include foods rich in probiotics.

Intervention Type OTHER

Lactose restriction

Diet will be restricted to 5g lactose/day

Intervention Type OTHER

Fiber restriction

Diet will be restricted to 20g fiber/day

Intervention Type OTHER

Fat restriction

Diet will be restricted to 20% total energy intake

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ability to understand the study and provide informed consent.
* ECOG: 0-2.
* Willingness to assist to every programed visit, to keep to the dietary intervention and lab tests.
* Diagnosed with cervical cancer.
* Clinical stages IB-2-IVA.
* Candidate to receive concomitant chemo-radiotherapy followed by brachytherapy.
* Disease measured by CT scan.
* No previous treatment based on chemo-radiotherapy. Hemoglobina levels \>10g/dL.
* Leucocytes \>4000/mm3.
* Platelets \> 100000/mm3.
* Adequate hepatic function.

Exclusion Criteria

* Patients under nutritional treatment or supplement.
* Patients with active uncontrolled infections.
* Patients under treatment with an experimental drug.
* Patients with fistula at the moment of diagnosis.
* Patients with previous malignancy.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No